The Cardiac Implants Market Size was valued at USD 40.33 Billion in 2023. The global cardiac implants industry is projected to grow from USD 44.85 Billion in 2024 to USD 97.13 Billion by 2032, exhibiting a CAGR of 8.97% during the forecast period (2024 - 2032).
Cardiac Implants are devices that can monitor the normal functions of the heart, detect fluctuations, and gives information about the heart. These implants are implanted in the heart to know the information about the heart. Moreover, the cardiac monitoring device implants can be used in the treatment of heart diseases like arrhythmias, myocardial ischemia, and acute myocardial infarction, among others.
Across the globe, the growing prevalence of cardiac diseases and rise in the older adult population are the major drivers that boost the growth of the market. The high-cost implant devices and risk of injection may be the restraints of the market growth over the forecast period.
COVID-19 Analysis:
Due to the COVID-19 outbreak, most of the markets like chemicals, automobiles, energy & power, agriculture, electronics, and medical implants are witnessing that reduction in growth rate. Due to government directions and hospital guidelines to the COVID-19 affected areas, the vascular procedures are reduced to life or limb salvaging cases. A new vascular procedure, endovascular therapy for triage of vascular surgery patients, should be introduced, but it was postponed due to the coronavirus effect.
The advanced technologies in medical implants can raise the growth of the Cardiac Implants industry. Additionally, availability of good medical facilities, hike in disposable income, awareness about the different types of medical implants is the factors helpful for the Cardiac Implants market growth. With government support, providing medical insurance coverage to downtrodden people for their better health leads to the demand for medical implants.
The Cardiac Implants Market is expected to register a CAGR of 7.82% and is anticipated to reach USD 38,054.3 million. Cardiac implants are devices implanted in the heart which monitor and maintain the normal functions of the heart. Cardiac implants monitor the condition of the heart, detect fluctuations, and provide this information to the doctor or the health care provider. Additionally, they are used in the treatment of heart diseases such as myocardial ischemia, arrhythmias, and acute myocardial infarction, among others.
The factors boosting the growth of the cardiac implants market include the growing prevalence of cardiac diseases and the growing population of older adults across the globe. Despite the drivers, the high cost associated with cardiac implants and risk of injections due to these implants may restrain the market growth over the forecast period.
The growth of the cardiac implants industry is driven by factors such as growing geriatric population coupled with the increasing prevalence of cardiac diseases. Generally, the older population is more susceptible to diseases as with aging, the heart and blood vessels become stiff which can lead to conditions such as heart failure, coronary artery disease, and atrial fibrillation, among others. According to the data published by the Centers for Disease Control and Prevention (CDC) in 2017, about 2.7 to 6.1 million people in the US had atrial fibrillation, a common form of heart arrhythmia. However, the high cost of cardiac implants are a risk of injections is likely to affect the growth of the market.
Cardiac Implants Market Revenue, by End User, 2022 (USD Billion)
Driver:
Rising Prevalence of Cardiac Disease and Geriatric Population
The rise in older adults and the rising prevalence of chronic diseases are the major drivers of the cardiac implant devices. Geriatric people are highly susceptible to chronic diseases like cardiovascular diseases, endovascular diseases, orthopedic disorders, and dental disorders, which are having the major need for medical implants. Generally, for aged people, dental disorder was a common problem. Hence with a rise in aged people, demand for tooth loss may increase. At the risk of a patient’s cardiac disorder, most healthcare organizations and hospitals prefer cardiovascular implants to provide artificial control on the patient’s heartbeat.
Restraint:
High Cost of Treatment and stringent approval process
Some cardiac patients may affect infections with implantable pacemakers, which makes them avoid these products. Thus reduces the demand for cardiac implants. The high cost of treatment is also a big burden for the normal ones. Hence the demand for cardiovascular implants growth decreases.
Opportunities:
Increase in Awareness and technological advancements
By increasing the awareness of different types of medical implants among healthcare professionals can boost the growth of the cardiac implants industry. By introducing the new advanced technologies in medical implants, the availability of better medical facilities, a large number of cases with damaged organs caused due to different types of accidents are the opportunities to increase the cardiac implants market share.
Technology Analysis
The new advanced technologies in medical implants are expected to increase the growth of the Cardiac Implants Industry.
Study Objectives -
To provide detailed information about the Cardiac Implants structure along with various forecast segments and sub-segments.
To provide the factors that affect the cardiac implants market share growth.
To analyze the cardiac implants market-based porter’s five force analysis, etc.
To provide the country-level analysis of the current cardiac implants market size and future prospective.
To provide country-level analysis of the cardiac monitoring device implants growth by region, device, indication, and end-user.
To provide a strategic profile of the key players in the market, analyze their core competencies, and draw a landscape of the cardiac implants market growth.
To track and analyze new product developments, strategic alliances, and research in the cardiac implants market.
The segmentation of the cardiac implants market was done based on the indication, device, region, and end-user.
Based on Indication, the global market is segmented into Arrhythmias, myocardial ischemia, acute myocardial infarction, heart failure, and others.
The cardiac implant devices are segmented into implantable loop recorder, cardiac rhythm management devices, coronary stents, ventricular assist devices, and others.
On the basis of the end-users, market of cardiac implants is segmented into cardiac care centers, ambulatory centers, hospitals, academic institutes, home care, and others.
Based on the region, the cardiac implants market is segmented to America, Europe, Asia-Pacific, and the Middle East & Africa. Further, America is segmented into North America and South America, Europe is segmented into Western Europe and Eastern Europe. Out of these, North America is holding the largest market share.
Regional Analysis
The Cardiac Implants Market is segmented based on the regions as Europe, America, Asia-Pacific, Middle East & Africa. Later, America is segmented into North America and South America. North America is expected to hold the largest market share for its high adoption rates of cardiac implantable electronic devices and an increase in the prevalence of cardiac diseases. In Europe, the global market is to grow for factors like increasing the government’s healthcare sector funds and increasing the number of initiatives for heart patients by the insurance companies.
In Europe 2017, Italy accounted for a market share of 9.9%. Asia-pacific is said to be the fastest-growing market for its increasing geriatric population, increasing medical tourism and change in lifestyle. For the presence of poor and slow developing countries in the Africa region, the Middle East & Africa accounts the least market share.
Competitive Landscape
The prominent and efficient key players in the market are as follows:
Abbott (US)
Amg International (Germany)
Edwards Life Sciences Corporation (US)
Braun Melsungen AG (Germany)
Biotronik(US)
Boston Scientific Corporation (US)
LivaNova PLC (UK)
Medtronic PLC (US)
Syncardia Systems, Inc (Arizona)
Terumo Corporation (Japan)
The key strategies followed by the players are product development, innovation, acquisition, and expansion.
One of the leading companies, Medtronic launched an advanced technology ICD device that allows patients to gather information by holding an antenna over the implanted cardiac device.
Recent Developments
In July 2018, in China, to enter the drug-eluting stent market, Terumo Corporation acquires China-based Essen Technology.
In February 2018, Medtronic launched 2.0mm Drug-Eluting Stent Resolute Onyx in the US. it is used by interventional cardiologists to treat patients with coronary artery disease (CAD).
In October 2015, Boston Scientific Corporation received the FDA for Synergy Bioabsorbable Polymer Drug-Eluting Stent System.
In August 2019, the U.S. FDA approved a heart implant that offers therapeutic stimulation to advanced heart failure patients. The Barostim Neo System is a cardiac neuromodulator device that stimulates baroreceptors in patients.
Report Overview:
The full report is inclusive of the following:
Market Overview
COVID-19 Analysis
Market Dynamics
Technology Analysis
Study Objectives
Segment Overview
Regional Analysis
Competitive Landscape
Recent Developments
Segmentation Table
FAQs
Coronary stents, Cardiac rhythm management devices, prosthetic heart valve devices, implantable loop recorder, and others.
Myocardial ischemia, arrhythmias, acute myocardial infarction, heart failure and others.
Hospitals, ambulatory centers, cardiac care centers, & home care, and others
America, Europe, Asia-Pacific, and the Middle-East & Africa
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)